Summarized by Masters of Longevity from Longevity Technology.
Mogrify reported preclinical proof-of-concept for in vivo retinal reprogramming therapy.
Key Takeaways
- Mogrify demonstrated retinal reprogramming in preclinical animal studies.
- The company plans to present the data on December 3, 2026.
- Animal findings remain preclinical and are not clinical proof.
